Results 211 to 220 of about 68,021 (347)

S1 Guideline: Therapy of generalized pustular psoriasis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner   +17 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri   +11 more
wiley   +1 more source

Prevalence of hypocalcemia in neonates receiving phototherapy: a systematic review and meta-analysis. [PDF]

open access: yesBMC Pediatr
Belayhun E   +13 more
europepmc   +1 more source

Out‐of‐pocket costs and time spent on disease management by vitiligo patients: a cross‐sectional questionnaire study in German‐speaking countries

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives The financial and time‐related burden of patients with vitiligo remains insufficiently studied. This study aimed to quantify out‐of‐pocket costs (OOPC) and time expenditure for vitiligo management and the associated sociodemographic, clinical, and behavioral factors in German‐speaking countries.
Christine Gasteiger   +5 more
wiley   +1 more source

Ropeginterferon‐α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pegylated interferon‐α2a became the off‐label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non‐pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon‐α2b in MF/SS. Patients and methods We performed a retrospective multicenter analysis at
Stefanie Porkert   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy